Vollmer, Johanna
Ecker, Jonas
Hielscher, Thomas
Valinciute, Gintvile
Ridinger, Johannes
Jamaladdin, Nora
Peterziel, Heike
van Tilburg, Cornelis M.
Oehme, Ina
Witt, Olaf
Milde, Till
Funding for this research was provided by:
Deutsche Krebshilfe (70113843)
Deutsches Krebsforschungszentrum (DKFZ)
Article History
Received: 4 August 2023
Accepted: 7 September 2023
First Online: 3 October 2023
Declarations
:
: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Cornelis M. van Tilburg participated in advisory boards of Novartis, Bayer and Alexion. Olaf Witt participated in advisory boards of Astra Zeneca, BMS, Novartis, Bayer, Roche and Janssen. Olaf Witt, Ina Oehme and Till Milde received research funding from Biomed Valley and Day One Therapeutics. Ina Oehme also from PreComb. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
: Not applicable.
: Not applicable.
: Not applicable.